

**REMARKS**

The benefit claim has been inserted on page 1 immediately following the title.


New page 33 has been added between page 32 and the beginning of the Sequence Listing to present the abstract of the application in a manner according to USPTO guidelines.

Pages 1 to 9 of the Sequence Listing were replaced with pages 1 to 11 of the Substitute Sequence Listing. The Substitute Sequence Listing adds the names of the inventors and prior application data in the heading in accordance with US practice. All sequences in the Sequence Listing and the Substitute Sequence Listing are the same.

Claims 1-4, 9-18, 20, 22, and 23 have been amended. Claims 5-8, 24 and 25 have been canceled. New claims 26-29 have been added. Thus upon entry of this amendment the pending claims will be 1-4, 9-23, and 26-29. The amendments have been made to bring the claims into better compliance with US standards by making editorial changes and eliminating multiple dependencies.

No new matter has been added by way of this amendment. Therefore, applicants respectfully request that the instant amendment be entered and received favorable consideration.

Respectfully submitted,



Gregory W. Warren  
Registration No. 48,385  
Telephone: 919-541-8646

Syngenta Biotechnology, Inc.  
3054 Cornwallis Road  
Research Triangle Park, NC 27709

Date: May 25, 2006